Want to see HK:1672 full AI Analyst Report?
Top Page
Ascletis Pharma, Inc.
(1672)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$9.50
â–¼(-5.94% Downside)
Action:Reiterated
Date:08/08/26
The score is held down primarily by weak financial performance (collapsing revenue, very negative profitability, and sustained high cash burn), only partly offset by low leverage on the balance sheet. Technicals provide modest support in the near term (above 20/50-day averages) but remain weaker longer term (below 100/200-day averages). Valuation is also constrained by ongoing losses (negative P/E) and no indicated dividend yield.
Positive Factors
Very low leverage
Minimal debt reduces solvency pressure and preserves financial flexibility. This gives Ascletis more capacity to fund research, commercial operations, or partnerships without relying primarily on additional borrowing.
Negative Factors
Severe revenue contraction
The sharp reduction in revenue indicates substantial commercial weakness and a very low current operating base. Until sales recover sustainably, the company has limited ability to absorb its fixed cost structure or fund development internally.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Minimal debt reduces solvency pressure and preserves financial flexibility. This gives Ascletis more capacity to fund research, commercial operations, or partnerships without relying primarily on additional borrowing.
Read all positive factors
Ascletis Pharma, Inc. (1672) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$10.60B
Dividend YieldN/A
Average Volume (3M)2.02M
Price to Earnings (P/E)―
Beta (1Y)1.03
Revenue Growth-59.39%
EPS Growth-130.04%
CountryHK
Employees202
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.37
Shares Outstanding1,057,769,000
10 Day Avg. Volume1,863,557
30 Day Avg. Volume2,018,821
Financial Highlights & Ratios
PEG Ratio-1.18
Price to Book (P/B)5.14
Price to Sales (P/S)4905.96
P/FCF Ratio-30.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$14.20Price Target Upside40.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.52
Revenue Forecast (FY)HK$11.87M
Ascletis Pharma, Inc. Business Overview & Revenue Model
Company Description
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GAN...
How the Company Makes Money
Ascletis primarily makes money through (1) product sales of its commercialized prescription drugs in its served markets, where revenue is recognized from selling finished pharmaceutical products through distribution channels to hospitals, pharmaci...
Ascletis Pharma, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
74
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.03M | 1.28M | 56.60M | 54.09M | 76.88M |
| Gross Profit | 527.00K | 735.00K | 25.99M | -24.69M | 39.17M |
| EBITDA | -471.65M | -390.45M | -126.09M | -284.50M | -169.35M |
| Net Income | -359.88M | -300.94M | -144.72M | -314.84M | -199.02M |
Balance Sheet | |||||
| Total Assets | 2.07B | 2.12B | 2.49B | 2.66B | 2.83B |
| Cash, Cash Equivalents and Short-Term Investments | 1.90B | 1.95B | 2.30B | 2.48B | 2.50B |
| Total Debt | 5.16M | 7.63M | 8.42M | 4.24M | 2.75M |
| Total Liabilities | 129.93M | 158.41M | 148.94M | 117.16M | 100.89M |
| Stockholders Equity | 1.94B | 1.97B | 2.34B | 2.54B | 2.73B |
Cash Flow | |||||
| Free Cash Flow | -330.83M | -343.73M | -163.32M | -156.85M | -154.13M |
| Operating Cash Flow | -329.23M | -341.58M | -144.16M | -142.45M | -146.93M |
| Investing Cash Flow | 565.97M | 978.91M | 149.84M | -1.30B | -274.49M |
| Financing Cash Flow | 336.29M | -103.51M | -81.50M | -1.42M | -31.10M |
Ascletis Pharma, Inc. Technical Analysis
Positive
10.10
Price Trends
10.06
Positive
12.12
Negative
13.27
Negative
Market Momentum
0.02
Negative
52.67
Neutral
66.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1672, the sentiment is Positive. The current price of 10.1 is below the 20-day moving average (MA) of 10.18, above the 50-day MA of 10.06, and below the 200-day MA of 13.27, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 52.67 is Neutral, neither overbought nor oversold. The STOCH value of 66.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1672.
Ascletis Pharma, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$22.97B | 25.34 | 12.35% | ― | 117.39% | ― | |
52 Neutral | HK$23.57B | -15.19 | -27.40% | ― | 5.38% | 16.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$10.60B | -14.64 | -28.15% | ― | -59.39% | -130.04% | |
47 Neutral | HK$9.74B | -19.63 | -43.54% | ― | 116.67% | -0.42% | |
46 Neutral | HK$34.66B | -78.10 | -7.32% | ― | 34.83% | 58.94% | |
45 Neutral | HK$12.97B | -7.70 | -153.78% | ― | 70.26% | -12.79% |
* Healthcare Sector Average
HK:1672
Ascletis Pharma, Inc.
10.18
-3.97
-28.06%
HK:9688
Zai Lab Ltd
20.00
-4.68
-18.96%
HK:9969
InnoCare Pharma Ltd.
14.76
-2.40
-13.99%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.86
-18.98
-51.52%
HK:2616
CStone Pharmaceuticals
6.18
-6.44
-51.03%
HK:6855
Ascentage Pharma Group International
34.20
-46.05
-57.38%
Ascletis Pharma, Inc. Corporate Events
Ascletis Widens Loss on R&D Surge as Obesity Drug Pipeline Advances
Aug 21, 2026
Ascletis Pharma has warned investors that it expects to post a loss attributable to shareholders of about RMB319.7 million for the six months ended June 30, 2026, a more than threefold increase from the RMB88.0 million loss a year earlier. Despite...
Ascletis Starts U.S. Phase I Trials for Ultra-Long-Acting Obesity Injections
Aug 10, 2026
Ascletis Pharma has initiated two Phase I obesity trials in the U.S. for ASC36, a once-monthly to once-quarterly amylin receptor peptide agonist, and ASC36_35FDC, a once-monthly fixed-dose combination of ASC36 with GLP-1R/GIPR dual agonist ASC35. ...
Ascletis launches global Phase III obesity trial and advances oral triple agonist portfolio
Aug 3, 2026
Ascletis Pharma has launched a global Phase III program for its once-daily oral GLP-1 small molecule candidate ASC30, targeting chronic weight management in about 4,600 obese or overweight patients across the U.S., Europe, and Canada. The trials w...
Ascletis Pharma Schedules Board Meeting to Review 2026 Interim Results and Dividend
Aug 3, 2026
Ascletis Pharma Inc. has announced that its board of directors will convene on August 31, 2026, to review and approve the interim financial results for the six months ended June 30, 2026. The board will also consider the potential declaration and ...
Ascletis Advances Once-Monthly Obesity Drug ASC37 With Strong Preclinical Results
Jul 27, 2026
Ascletis Pharma reported new preclinical data showing its triple peptide agonist ASC37 delivered significantly greater weight loss than tirzepatide in diet-induced obese mice at equivalent doses. In 11-day dosing, ASC37 produced up to 41.5% body w...
Ascletis Showcases Preclinical Obesity Drug with Superior Weight-Loss Data at EASD 2026
Jul 23, 2026
Ascletis Pharma announced that preclinical data for its fixed-dose combination ASC36_35, a once-monthly subcutaneous injection co-formulation of an amylin receptor agonist and a dual GLP-1R/GIPR agonist, will be presented in an oral discussion at ...
Ascletis Advances First-in-Class Oral GLP/GIP Combo for Obesity
Jul 15, 2026
Ascletis has selected a fixed-dose combination of its in-house oral GIPR agonist ASC48 and oral GLP-1R agonist ASC30 for clinical development as a once-daily obesity pill. Preclinical data show ASC48 has higher GIPR potency than tirzepatide and fa...
Ascletis files U.S. INDs for next‑generation monthly obesity injections
Jul 6, 2026
Ascletis Pharma has submitted two Investigational New Drug applications to the U.S. FDA for ASC36, a next-generation peptide amylin receptor agonist, and ASC36_35, a once-monthly co-formulation combining ASC36 with GLP-1R/GIPR agonist ASC35 for ob...
Ascletis Pharma Launches HK$300 Million Share Buyback Under Mandate
Jun 30, 2026
Ascletis Pharma Inc. announced that its board intends to utilize an existing share repurchase mandate, allowing buybacks of up to 106,137,084 shares, or 10% of issued share capital, on the Hong Kong open market. The company plans to allocate up to...
Ascletis Pharma Wins Shareholder Backing for All AGM Resolutions and Capital Mandates
Jun 29, 2026
Ascletis Pharma shareholders approved all resolutions at the 29 June 2026 annual general meeting, including the 2025 audited financial statements, re-election of directors, and reappointment of KPMG as auditor. Voting was conducted by poll, with m...
Ascletis Wins FDA Green Light for Monthly Obesity Drug ASC35 Phase I Trial
Jun 23, 2026
Ascletis Pharma has received U.S. FDA clearance for an Investigational New Drug application to begin a Phase I trial of ASC35, a once-monthly subcutaneous GLP-1R/GIPR dual peptide agonist for treating obesity and overweight patients with related c...
Ascletis Showcases Differentiated Oral Obesity Drugs at ADA 2026
Jun 8, 2026
Ascletis Pharma highlighted progress in its obesity portfolio at the American Diabetes Association 2026 Scientific Sessions, presenting data on its oral GLP-1 receptor agonist ASC30, oral amylin receptor agonist ASC39, and peptide delivery technol...
Ascletis Pharma Sets 2026 AGM and Seeks Renewal of Share Issuance Mandate
Jun 5, 2026
Ascletis Pharma has called its 2026 annual general meeting for June 29 in Hong Kong to review the 2025 audited financial statements and the reports of directors and the auditor. Shareholders will also vote on the re-election of executive director ...
Ascletis Pharma Seeks Shareholder Approval to Modernize Governance Rules
Jun 2, 2026
Ascletis Pharma Inc. plans to replace its existing articles of association with a third amended and restated memorandum and articles to align its corporate governance framework with updated Hong Kong Listing Rules. The proposed changes focus on en...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.